SAPS-018 - The cost-effectiveness analysis of maintaining disease remission in atopic dermatitis patients using Abrocitinib and Dupilumab: From the perspective of healthcare payers

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: SAPS-018
• By: CHEN, Jack Yu-Chieh (China Medical University Hospital, China Taiwan)
• Co-author(s): Dr Jack Yu-Chieh Chen (China Medical University Hospital, Taichung, China Taiwan)
  
• Abstract:

  Background:
  Atopic dermatitis (AD) is a common chronic, recurrent inflammatory skin disease affecting up to 20% of children and 10% of adults. Its pharmacological treatment is divided into three lines: the first-line treatments include topical corticosteroids and antihistamine skin anti-itch agents; the second line involves topical calcineurin..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login